CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

* Erforderlich

Your name *

First Last

Tanja Birrenbach

Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada

Department of Emergency Medicine, Inselspita

Your e-mail address * abc@gmail.com

Tanja.Birrenbach@insel.ch

Title of your manuscript * Provide the (draft) title of your manuscript.

Effectiveness and utility of virtual reality simulation as educational tool for safe performance of COVID-19 diagnostics: a prospective, randomized pilot trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

CVRSB (Covid19 - VR strikes back

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

V1.1.6

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

english, German, Chinese

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

http://elearn.oramavr.com/cvrsb/

URL of an image/screenshot (optional)

Meine Antwort

Accessibility * Can an enduser access the intervention presently?



) access only for special usergroups, not open

) access is open to everyone, but requires payment/subscription/in-app purchases

) app/intervention no longer accessible

) Sonstiges:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

COVID-19

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

(i) the short- and long-term effectiveness of a

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Meine Antwort

Recommended "Dose" * What do the instructions for users say on how often the app should be used?

0	Approximately Daily
0	Approximately Weekly
0	Approximately Monthly
0	Approximately Yearly
۲	"as needed"
\bigcirc	Sonstiges:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

unknown / not evaluated

- 0-10%
- 0 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- O Sonstiges:

Overall, was the app/intervention effective? *
O yes: all primary outcomes were significantly better in intervention group vs control
partly: SOME primary outcomes were significantly better in intervention group vs control
O no statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
O Sonstiges:

Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
not submitted yet - in late draft status, just before submission
Submitted to a journal but not reviewed yet
Submitted to a journal and after receiving initial reviewer comments
Submitted to a journal and accepted, but not published yet
O published
O Sonstiges:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)



-) JMIR Serious Games
-) JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Sonstiges:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *
Pilot/feasibility
O Fully powered
Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms
tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
o ms number (yet) / not (yet) submitted to / published in JMIR
O Sonstiges:
TITLE AND ABSTRACT
1a) TITLE: Identification as a randomized trial in the title
1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
• yes
O Sonstiges:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.




Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

it states "virtual reality simulation" in the title



Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

1a-iii) Primary condition or target group in the title								
Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial								
	1	2	3	4	5			
subitem not at all important	0	0	۲	0	0	essential		
					Au	swahl löschen		

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES,


"Effectiveness and utility of virtual reality simulation as educational tool for safe performance of COVID-19 diagnostics"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-i?*


Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"Explore the short- and long-term effectiveness of a fully immersive VR simulation vs. a traditional learning method regarding a COVID related skillset and media-specific variables influencing training outcomes."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Meine Antwort

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)



Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"The coronavirus pandemic is a global health emergency that places massive demands on health systems and health care workers (1). Proper use of hygiene and personal protective equipment (PPE) is paramount to prevent spreading of disease and contamination of healthcare workers. One possible reason for the high infection rate is ineffective use of PPE. In Italy, up to 20% of healthcare workers were initially infected (2).

PPE recommendations from international organizations are largely consistent (CDC, WHO) (3-6); however, the actual use of PPE is not: healthcare personnel of all professions and at all levels of training uses incorrect techniques for donning and doffing of PPE and hand hygiene (7-11). The main reason appears to be inadequate training in correct PPE technique and lacking assessment of proficiency (7,11,12).


Simulation proves to be a powerful tool to test the accurate use of hygiene skills relevant for the treatment of COVID patients (i.e. PPE and hand hygiene) (13), nevertheless, there is still ambiguity which training method works best. A recent Cochrane review of evidence relating to PPE and protection of healthcare staff exposed to contaminated body fluids highlights the lack of robust evidence in this area (11).

Furthermore, education and training of healthcare personnel is difficult with social distancing restrictions in place and shortage of PPE (2) as well as testing material. Virtual reality (VR) simulation with the use of head-mounted devices (HMDs) can offer a multisensory, three-dimensional, fully immersive, and safe training opportunity, avoiding the restrictions of social distancing and material shortages (14,15). The value of VR in medical education has already been demonstrated for various tasks, especially but not exclusively in surgical skills training (14,16–27). Recent studies suggest that VR improves post intervention knowledge and skills of health professionals better than traditional education or other types of digital education (18,28). VR offers several advantages, as it allows possibilities for flexible learning and self-learning, providing standardization, reproducibility and stimuli control, enabling large automated data generation with the possibility of giving automated individualized feedback (21). The initial cost and effort creating the program can easily be compensated by broad distribution (14,29), as VR training is gradually finding its way into the medical curriculum (30).

Few virtual or mixed reality simulations exist for training hand hygiene with different learning objectives, varying complexity of implementation and hardware requirements (31–34). In addition, studies evaluating the effectiveness and long-term retention of a VR simulation compared to conventional training methods are missing. "

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"Virtual reality (VR) simulation with the use of head-mounted devices (HMDs) can offer a multisensory, three-dimensional, fully immersive, and safe training opportunity, avoiding the restrictions of social distancing and material shortages (14,15). The value of VR in medical education has already been demonstrated for various tasks, especially but not exclusively in surgical skills training (14,16–27). Recent studies suggest that VR improves post intervention knowledge and skills of health professionals better than traditional education or other types of digital education (18,28). VR offers several advantages, as it allows possibilities for flexible learning and self-learning, providing standardization, reproducibility and stimuli control, enabling large automated data generation with the possibility of giving automated individualized feedback (21). The initial cost and effort creating the program can easily be compensated by broad distribution (14,29), as VR training is gradually finding its way into the medical curriculum (30).

Few virtual or mixed reality simulations exist for training hand hygiene with different learning objectives, varying complexity of implementation and hardware requirements (31–34). In addition, studies evaluating the effectiveness and long-term retention of a VR simulation compared to conventional training methods are missing. "

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

yes

"Therefore, we performed a randomised controlled pilot study in medical students to explore (i) the short- and long-term effectiveness of a fully immersive VR simulation vs. a traditional learning method regarding a COVID related skillset (i.e. proper hand hygiene, proficiency in PPE use and correct acquisition of a nasopharyngeal specimen) tested in a simulated clinical scenario

(ii) media-specific variables influencing training outcomes, such as usability, satisfaction, simulator sickness, and the experience of presence and immersion."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"This is a prospective randomized controlled pilot study, taking place at the Emergency Department (ED) of the Inselspital, University Hospital Bern, Switzerland (35), from September to November 2020."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no changes to methods after trial commencement

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Au	swahl löschen

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. "Inclusion criteria were as follows: medical students (year 3-6 out of a 6-year curriculum) at the University of Bern.

Exclusion criteria consist of unwillingness to participate or to provide informed consent."

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0		
					Au	swahl löschen


Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was a face-to-face trial, involving independent raters blinded to the intervention assessing the participants performance

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES,

"This is a prospective randomized controlled pilot study, taking place at the Emergency Department (ED) of the Inselspital, University Hospital Bern, Switzerland (35), from September to November 2020."

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.



Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study consisted of several outcomes that were assessed by an independent rater (ie hand desinfection, Obtaining the nasopharyngeal swab and evaluation of contamination during doffing of PPE. as well as surveys that were filled out by the participants after the assessments

4b-ii) Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item - describe only if this may bias results) 1 2 3 4 5 subitem not at all important Im

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and

owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Au	swahl löschen

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

One author is co founder of the company who developed the VR Simulation, this is revealed in the affiliations and COI

5-ii) Describe the history/development process Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.								
	1	2	3	4	5			
subitem not at all important	۲	0	0	0	0	essential		
					Au	swahl löschen		


Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

Meine Antwort

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting. 2 3 1 4 5 0 0 \bigcirc subitem not at all important essential

Does your paper address sul	bitem 5 [.]	-v?				
Copy and paste relevant sections fro indicate direct quotes from your man information not in the ms, or briefly e	nuscript), c	or elaborat	e on this it	tem by pro	viding add	litional
the VR simulation is available fo	r free at t	the webs	te			
E-vi) Digital procervation						
5-vi) Digital preservation		- 1: 4 :				
Digital preservation: Provide the URL disappear over the course of the year <u>webcitation.org</u> , and/or publishing th pages behind login screens cannot b without login.	rs; also ma ne source c	ake sure th code or sci	ie interven reenshots,	ntion is arc /videos ale	hived (Inte	ernet Archive, e article). As
	1	2	3	4	5	
subitem not at all important		0	0	0	0	essential

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"The study population consists of a convenience sample of medical students at the University of Bern. All participants attended on a voluntary basis; no remuneration was provided. Informed consent was obtained. Data were collected, analysed, and stored in anonymized form. "

"Inclusion criteria were as follows: medical students (year 3-6 out of a 6-year curriculum) at the University of Bern.

Exclusion criteria consist of unwillingness to participate or to provide informed consent."

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The intervention group was trained in COVID related skills using the VR simulation (CVRSB (Covid19 – VR strikes back) module, version 1.1.6, software platform, developed by ORamaVR (Heraklion, Crete, Greece) and the Oculus Rift S head mounted device and hand controllers (Facebook Inc., Menlo Park, California, USA). The software is available for free (38) (Figure 4).

The participants had two runs in the simulation using the single player modus. "

5-ix) Describe use parameters


Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?	
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	
Meine Antwort	

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there were no reminders used as the simulation was only accessed in training during the trial

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.



Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There was no co-intervention used

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

E

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

yes. Assessments and measurements are detailed in the METHODS section:

"Assessments/Measurements

We evaluated the performance of hand disinfection and performance in taking a nasopharyngeal swab on a manikin as well as contamination during doffing of PPE (Figure 1).

Hand disinfection

Hand disinfection performance was evaluated employing fluorescent marker (Visirub® conc and Sterillium®, Hartmann AG, Heidenheim, Germany) and UV-light scanning using the Derma Litecheck UV® Multimedia (KBD Ltd, Weinheim, Germany) at the time of enrolment (pre-test), directly after the intervention (post-test no. 1), and 1 month after the intervention (post-test no. 2). Participants were blindfolded during assessment and unable to assess their results. A performance analysis scheme (documentation of missed locations; n=38 location for each hand, all together 76 areas investigated) was developed by the institution's infection control and medical educator team adapted from Pan et al. (36). Outcome was the number of missed locations (range from zero to 76, the less the better). Performance was supervised by an independent and trained rater, the images were electronically recorded and analysed according to the predefined scheme (Figure 2 and 3).

Obtaining the nasopharyngeal swab and evaluation of contamination during doffing A simulation setup for conducting a nasopharyngeal swab for Covid-19 testing on a manikin (Little Anne[™], Laerdal Medical, Stavanger, Norway) using proper hand-hygiene and PPE was installed.

The correct procedure of taking a nasopharyngeal swab sample as well as possible contamination while doffing was evaluated directly after the intervention (post-test no. 1), and 1 month after the intervention (post-test no. 2).

An independent and trained rater blinded to the intervention assessed each participant's performance using a 17-item checklist adapted from (8,10) based on the CDC guidelines (3,6), WHO guidelines for hand hygiene (5) and international recommendations for taking a nasopharyngeal swab (37), that was developed by the institution's infection control and medical educator team (Supplementary Table S1). Outcome was the number of points achieved on the checklist (range 0 to 17, the more the better).

Contamination during the procedure was evaluated using fluorescent lotion (Dermalux® Testlotion S, KBD Ltd, Weinheim, Germany), applied to the participants' hands, forearms and torso before doffing of PPE. Ten areas (right hand, right forearm, right upper arm, left hand, left forearm, left upper arm, torso ventral, torso dorsal, neck, head/ears) were analysed by UV-lighting for contamination after doffing by an independent rater. Outcome was the number of contaminated areas (range from zero to 10, the less the better). Intervention

Participants were randomized to either the intervention group (VR simulation) or control group in a 1:1 ratio using a computer-generated system.

VR Simulation

:

The intervention group was trained in COVID related skills using the VR simulation (CVRSB (Covid19 – VR strikes back) module, version 1.1.6, software platform, developed by ORamaVR (Heraklion, Crete, Greece) and the Oculus Rift S head mounted device and hand controllers (Facebook Inc., Menlo Park, California, USA). The software is available for free (38) (Figure 4).

The participants had two runs in the simulation using the single player modus.

Control group

The control group was trained using traditional learning methods (printed instructions, local instruction videos on COVID related skills, i.e. PPE donning and doffing, as well as formal videos on proper hand hygiene according to the WHO and on taking a correct nasopharyngeal sample (37).

Intervention survey

Evaluation of both groups regarding variables of media use was carried out according to established questionnaires.

Usability for both training modules was assessed using the After-Scenario Questionnaire (ASQ) (39), which assesses the ease of task completion, satisfaction with completion time and satisfaction with supporting information on a 7-point Likert scale (total score ranges from 1=full satisfaction to 7=poor satisfaction).

The User Satisfaction Evaluation Questionnaire (USEQ) has six questions with a five-point Likert scale to evaluate user satisfaction (total score ranges from 6=poor satisfaction to 30=excellent satisfaction) (40).


For the VR-simulation, "visually-induced motion sickness" was assessed with four items (nausea, headache, blurred vision, dizziness) according to the Simulator Sickness Questionnaire (SSQ) adapted from Kennedy et al. (total score ranges from 1=no simulator sickness to 5=strong simulator sickness) (41).

Presence and immersion in the virtual world was determined according to the six-item questionnaire developed by Slater-Usoh-Steed (total score ranges from 1=no immersion to 7=full immersion) (42). "

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were

designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].



Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text

no online questionnaires were used

Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/add reported in any ehealth trial.						
	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					Au	swahl löschen
Does your paper address sub Copy and paste relevant sections from Meine Antwort						
Copy and paste relevant sections from Meine Antwort 6a-iii) Describe whether, how was obtained	n manusc	ript text /hen qua				
Copy and paste relevant sections from Meine Antwort 6a-iii) Describe whether, how	n manusc 1, and w litative fe	ript text /hen qua edback fro				
Copy and paste relevant sections from Meine Antwort 6a-iii) Describe whether, how was obtained Describe whether, how, and when qua	n manusc 1, and w litative fe	ript text /hen qua edback fro	om particip			
Copy and paste relevant sections from Meine Antwort 6a-iii) Describe whether, how was obtained Describe whether, how, and when qua	n manusc /, and w litative fe ocus grou	ript text /hen qua edback fro ps). 2	om particip	oants was	obtained (

Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

Meine Antwort

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no changes to trial outcomes after the trial commenced

7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.



Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

as this was a pilot trial, no formal sample size calculation was done

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there were no interim analyses or stopping guidelines

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"Participants were randomized to either the intervention group (VR simulation) or control group in a 1:1 ratio using a computer-generated system."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there were no restrictions, such as blocking in the randomisation process

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Randomisation was carried out using computer generated randomisation

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Randomisation was carried out using computer generated randomisation

Participants were enrolled by the study team, i.e. TB, JZ, TCS

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't.
Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).
1
2
3
4
5
subitem not at all important
O
O
O
O
essential
Auswahl löschen

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were not blinded to intervention, but partially blinded to outcomes (i.e. hand desinfection was assessment with the participants blindfolded)


Raters:

Hand-desinfection:

"Performance was supervised by an independent and trained rater, the images were electronically recorded and analysed according to the predefined scheme."

nasopharyngeal swab sample as well as possible contamination while doffing: "An independent and trained rater blinded to the intervention assessed each participant's performance using a 17-item checklist adapted from (8,10) based on the CDC guidelines (3,6), WHO guidelines for hand hygiene (5) and international recommendations for taking a nasopharyngeal swab (37), that was developed by the institution's infection control and medical educator team (Supplementary Table S1). Outcome was the number of points achieved on the checklist (range 0 to 17, the more the better).

Contamination during the procedure was evaluated using fluorescent lotion (Dermalux® Testlotion S, KBD Ltd, Weinheim, Germany), applied to the participants' hands, forearms and torso before doffing of PPE. Ten areas (right hand, right forearm, right upper arm, left hand, left forearm, left upper arm, torso ventral, torso dorsal, neck, head/ears) were analysed by UV-lighting for contamination after doffing by an independent rater. Outcome was the number of contaminated areas (range from zero to 10, the less the better)."



Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No placebo or sham intervention was used

12a) Statistical methods used to compare groups for primary and secondary

outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

statistical methods are detailed in the METHODS section: "Data was analysed in SPSS Statistics (Version 22 (IBM Zurich, Switzerland) and Stata 16.1 (StataCorp, The College Station, Texas, USA). Baseline characteristics are presented as numbers and percentage or median and interquartile range (IQR) using descriptive statistics as appropriate. Intervention and control group are compared regarding the baseline characteristics by means of Chi-square test and Wilcoxon-rank sum test as applicable. For the comparison of all four outcome groups – i.e. i) the number of missed areas during hand disinfection, ii) achieved items from the 17-item checklist during nasopharyngeal swab acquisition, iii) the number of contaminated areas during doffing, and iv) variables of media use – at a specific time-point between the study groups the Wilcoxon-rank sum test was used. With-in group differences for different time-points were tested using Wilcoxon matched-pairs signed-rank test.

For all tests, a P-value < .05 is considered significant. For this pilot study, no adjustment for multiple testing was performed. Furthermore, pairwise comparisons were favoured over more complex analysis, such as mixed linear regression analysis."

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there were no drop-outs/missing data

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

to

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
no subgroupd analyses were carrried out

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics co	ommitte	ee appro	oval			
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					Au	swahl löschen

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The local ethics committee deemed our study exempt from full ethical approval (BASEC-No: Req-2020-00889)."

Dutline informed consent procedures etc.?), and what information was prov consent documents.					•	
	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Au	swahl löschen


Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary

outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

as there were no drop outs, the number of participants assigned, received training and were analysed are the same

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there were no losses or exclusions after randomisation

13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement. 1 2 3 4 5 subitem not at all important Important

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"This is a prospective randomized controlled pilot study, taking place at the Emergency Department (ED) of the Inselspital, University Hospital Bern, Switzerland (35), from September to November 2020."

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"



Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the trial did not end early

15) A table showing baseline demographic and clinical characteristics for each group

group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES, there is a table showing the baseline characteristics

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Au	swahl löschen

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"A brief survey about sociodemographic factors, prior training, and experience in hand hygiene and PPE use, taking of respiratory samples (nasopharyngeal swab) as well as prior experience with VR was performed after enrolment."

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions


Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The number of participants is included in each analysis and shown in the result tables



Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

median and IQR are detailed for both groups

17a-i) Presentation of process outcomes such as metrics of use and intensity of

use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

there are no binary outcomes

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory


Does your paper address CONSORT subitem 18?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

no subgroup analyses were performed

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).



Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)


Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES, Simulator Sickness, a common unintended effect in VR Simulations, is assessed

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].



Does your paper address subitem 19-i?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no privacy breaches

19-ii) Include qualitative feedback from participants or observations from

staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.



Does your paper address subitem 19-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

User satisfaction was assessed in the intervention survey

considering other relevant of NPT: In addition, take into account the expertise of care providers or center	evidenc ne choice d	e of the com		•		harms, and
22-i) Restate study question starting with primary outcor Restate study questions and summa outcomes and process outcomes (us	nes and rize the an	process	s outcor	nes (use	e)	
		\sim	J O	4	Ĵ	
subitem not at all important	\bigcirc	\cup		\bigcirc	\bigcirc	essential

YES

"In this study, we demonstrated that our VR simulation was similarly effective, and partly even more effective than traditional learning methods in training medical students in COVID related skills, i.e. the correct performance of hand hygiene, use of personal protective equipment, and execution of obtaining a nasopharyngeal swab specimen. "



Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES

"We were able to show that the observed learning effect was maintained over the observed timeframe of one month in both learning groups. Whether there is a difference in skill decay between the two learning methods in the long run remains an important open question."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					Au	swahl löschen

Does your paper address subitem 20-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. limitations are discussed in the limitations section:

"This study has several limitations, including its single center design restricting external validity. The number of participants in our study was limited due to the large logistical and human resources required to conduct the study during a pandemic. Therefore, the detection of small differences between training modalities is not possible with our study design. There is the possibility of selection bias, based on volunteer convenience sampling of medical students, as well as a possible performance bias, with allocation to the interventional group leading to higher motivation, satisfaction and performance.


Furthermore, the correlation of these findings to clinical, patient-oriented outcomes remains to be validated."

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YES. limitations are discussed in the limitations section:

"This study has several limitations, including its single center design restricting external validity. The number of participants in our study was limited due to the large logistical and human resources required to conduct the study during a pandemic. Therefore, the detection of small differences between training modalities is not possible with our study design. There is the possibility of selection bias, based on volunteer convenience sampling of medical students, as well as a possible performance bias, with allocation to the interventional group leading to higher motivation, satisfaction and performance.

Furthermore, the correlation of these findings to clinical, patient-oriented outcomes remains to be validated."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					Au	swahl löschen

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

As this was a pilot trial involving medical students but not patients there was no formal trial registration

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24?*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the trial protocol is described in the manuscript

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Sources of funding and other COI are detailed in the COI section

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention. I</t

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

this is adressed in the COI section

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

-) yes, major changes
- yes, minor changes
-) no

What were the most important changes you made as a result of using this checklist?

Conflict of interest statement

90 minutes As a result of using this checklist, do you think your manuscript has improved? * yes no Sonstiges: Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" as PDF") before you submit it.	How much time did you spend on making changes in your manuscri	going through the checklist INCLUDING pt *					
 yes no Sonstiges: Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	90 minutes						
 no Sonstiges: Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	As a result of using this checklist,	do you think your manuscript has improved? *					
 Sonstiges: Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a 	O yes						
 Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes no Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	o no						
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document yes • no • Sonstiges: • Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	O Sonstiges:						
Sonstiges: Auswahl löschen Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	This would involve for example becoming in "Explanation and Elaboration" document O yes	- .					
Any other comments or questions on CONSORT EHEALTH Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a							
Meine Antwort STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	o conoliges.	Auswahl löschen					
STOP - Save this form as PDF before you click submit To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	Any other comments or questions	s on CONSORT EHEALTH					
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a	Meine Antwort						
		•					

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Senden

Geben Sie niemals Passwörter über Google Formulare weiter.

Dieser Inhalt wurde nicht von Google erstellt und wird von Google auch nicht unterstützt. <u>Missbrauch melden</u> - <u>Nutzungsbedingungen</u> - <u>Datenschutzerklärung</u>

